Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
June 2013, Vol 4, No 5
June 2013, Vol 4, No 5
Companion Diagnostics Information Not Easily Obtained
By
Charles Bankhead
Personalized Medicine
June 2013, Vol 4, No 5
Getting technical information about companion diagnostic tests required to make formulary decisions about oncology drugs may not be easy, according to a small telephone survey conducted by Aashish Surti, PharmD candidate, and Iris Tam, PharmD, Director, Managed Care Medical Communications, Genentech. They reported their survey results in a poster presented at the 2013 Academy of Managed Care Pharmacy (AMCP) meeting.
Read Article
Urologists’ Prescribing of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer Vary by Practice Affiliation
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
An analysis comparing the prescribing habits of urology practices shows that, despite treatment guideline recommendations to the contrary, gonadotropin-releasing hormone (GnRH) agonists, which are only indicated for the palliative treatment of advanced prostate cancer, are routinely prescribed for patients with localized, low- or intermediate-grade prostate cancer, particularly by urologists who have no practice affiliation with a medical school.
Read Article
Single, Older Women Less Likely to Receive Guideline- Recommended Treatment for Breast Cancer in Rural Georgia
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
;Researchers looking at whether guideline-directed adjuvant treatments for breast cancer were actually being administered in rural areas of the United States found that only 41% of the patients in this study received all of the suggested treatment modalities for breast cancer.
Read Article
Use of High-Cost Tests for Lung Cancer Surveillance Rising
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
The use of costly diagnostic imaging of uncertain value is increasing rapidly for patients with localized non–small-cell lung cancer (NSCLC), according to data from the Surveillance, Epidemiology and End Results (SEER)-Medicare database.
Read Article
Medicare Committee Gives Thumbs Down to New Genetic Tests for Cancer
By
Ross D. Margulies, JD, MPH
;
Jayson Slotnik, JD, MPH
Health Policy
,
Policies & Guidelines
June 2013, Vol 4, No 5
Mr Margulies is an Associate, Foley Hoag, LLP, and Mr Slotnik is a Partner, Health Policy Strategies, LLC, Washington, DC
Read Article
Immunotherapies Take Center Stage in Melanoma
By
Audrey Andrews
ASCO Annual Meeting
,
ASCO
June 2013, Vol 4, No 5
Chicago, IL—Data continue to build for the application of immunotherapy for patients with metastatic melanoma. At the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), several sessions were devoted to recent advances in melanoma, focusing on new ways to boost the activity of current therapies, introducing a new class of immunotherapy in development, and a new form of immunotherapy—an oncolytic vaccine.
Read Article
Prostate Cancer Risk Doubles in Men with Lynch Syndrome
In the Literature
June 2013, Vol 4, No 5
Lynch syndrome (LS) is an inherited syndrome of predisposition to cancer with an increased risk for colorectal cancer ranging from 30% to 80%. Prostate cancer has been described as a component tumor of LS, but the lifetime risk of prostate cancer in patients with LS has not been quantified because of inherent difficulties. In a new analysis, researchers have used genetic data to define the risk of prostate cancer in men with LS (Raymond VM, et al.
J Clin Oncol
. 2013;31:1713-1718).
Read Article
Crizotinib Superior to Standard Chemotherapy in Patients with ALK-Positive Lung Cancer
In the Literature
June 2013, Vol 4, No 5
Read Article
Rituximab Maintenance Prolongs PFS in Patients with Relapsed Lymphoma
In the Literature
June 2013, Vol 4, No 5
Read Article
Bevacizumab an Effective New Treatment Option for Relapsed Cervical Cancer
By
Wayne Kuznar
ASCO Annual Meeting
,
ASCO
June 2013, Vol 4, No 5
Chicago, IL—Adding bevacizumab (Avastin) to standard chemotherapy improves overall survival (OS) in women with metastatic or relapsed cervical cancer, representing the first instance in which a targeted therapy has significantly prolonged OS in this patient population.
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma